Disease landscape

Follicular Lymphoma clinical trials

Get alerts when Follicular Lymphoma trials change

272 active trials 142 recruiting 30 Phase 3 153 sponsors 29 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-09-16

What changed in the last 30 days

2026-09-12
Recruitment suspended
Recruitment suspended: Insufficient funding
NCT07098364 ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in… · Fred Hutchinson Cancer Center · Phase 1/2
2026-09-12
Primary completion pushed: 2026-03-09 → 2029-04-28
Completion pushed: 2026-05-11 → 2029-09-18
NCT06830031 Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell… · Shanghai Exuma Biotechnology Ltd. · Phase 1
2026-09-05
Primary completion pushed: 2026-09-01 → 2028-09-01
NCT06043323 A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR)… · M.D. Anderson Cancer Center · Phase 2
2026-08-28
Primary completion pushed: 2026-08-12 → 2027-08-12
Completion pushed: 2027-02-12 → 2028-02-12
NCT06442475 Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma · University of Washington · Phase 2
2026-08-27
Primary completion pushed: 2026-08-11 → 2027-08-10
Completion pushed: 2026-08-11 → 2027-08-10
NCT06112847 Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma · City of Hope Medical Center · Phase 2
2026-08-28
Primary completion pushed: 2026-07 → 2027-07
Completion pushed: 2026-07 → 2027-07
NCT04464200 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers · Memorial Sloan Kettering Cancer Center · Phase 1
2026-08-21
Primary completion pushed: 2026-08-01 → 2027-08-01
Completion pushed: 2027-08-01 → 2028-08-01
NCT04007029 Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or… · Jonsson Comprehensive Cancer Center · Phase 1
2026-08-22
Primary endpoint(s) modified
NCT05006716 A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With… · BeOne Medicines · Phase 1/2
2026-08-29
Enrollment closed, study ongoing
Final enrollment: 39 participants (planned 154)
NCT05512390 A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously… · AbbVie · Phase 1
2026-09-12
Enrollment closed, study ongoing
Trial sites reduced: 24 → 20 locations
NCT06492837 Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients · Fondazione Italiana Linfomi - ETS · Phase 2
2026-09-10
Recruitment opened
NCT07225439 Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of… · Paolo Caimi, MD · Phase 1
2026-09-01
Enrollment reopened
Enrollment increased: 33 → 83 participants
NCT06108232 Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High… · M.D. Anderson Cancer Center · Phase 2
2026-09-10
Enrollment increased: 705 → 845 participants
NCT05326308 Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic… · iOMEDICO AG
2026-09-04
Trial sites expanded: 21 → 24 locations
NCT07634471 A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) · Merck Sharp & Dohme LLC · Phase 2/3
2026-08-20
Trial sites expanded: 224 → 228 locations
NCT06549595 A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular… · AstraZeneca · Phase 3
2026-08-19
Primary completion moved earlier: 2026-09-11 → 2023-10-24
NCT03198026 Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent… · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · Phase 2
2026-08-22
Completion pushed: 2026-07-01 → 2027-06-02
NCT03150329 Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. · City of Hope Medical Center · Phase 1
2026-09-06
Trial status changed: Active, Not Recruiting → Unknown
NCT05749549 Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers · Shanghai Blueray Biopharma Co., Ltd. · Phase 1/2
2026-09-06
Trial status changed: Active, Not Recruiting → Unknown
NCT00877214 Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas · Jurgen Barth · Phase 3
2026-09-06
Trial status changed: Recruiting → Unknown
NCT04097067 ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma · University Hospital Muenster

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-08-26 NCT07788118 A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell… Second Affiliated Hospital, Zhejiang University, School of Medicine new Phase 1/2
2026-08-06 NCT07750886 Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin… Natera, Inc. new
2026-07-30 NCT07735533 A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies Umoja Biopharma new Phase 1/2
2026-07-30 NCT07736950 A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without… Australasian Leukaemia and Lymphoma Group new Phase 3
2026-07-22 NCT07719855 A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of… Ruijin Hospital new Phase 3

Active trials by phase

Early Phase 1
3
Phase 1
63
Phase 1/2
40
Phase 2
90
Phase 2/3
3
Phase 3
27
Not charted: 46 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 272

NCT IDTitleSponsorStatusUpdated
Phase 3
NCT06091254 A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works… Regeneron Pharmaceuticals Recruiting 2026-09-11
NCT06337318 Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden… National Cancer Institute (NCI) Recruiting 2026-09-10
NCT05929222 Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage… Fondazione Italiana Linfomi - ETS Recruiting 2026-09-08
NCT06549595 A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular… AstraZeneca Recruiting 2026-08-19
NCT06149286 A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better… Regeneron Pharmaceuticals Recruiting 2026-08-14
NCT07562022 A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in… Sinocelltech Ltd. Recruiting 2026-08-13
NCT01804686 A Long-term Extension Study of PCI-32765 (Ibrutinib) Janssen Research & Development, LLC Recruiting 2026-07-31
NCT06284122 Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy… The Lymphoma Academic Research Organisation Recruiting 2026-06-05
NCT06911502 A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab… Celgene Recruiting 2026-05-20
NCT05045664 Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody Heidelberg University Recruiting 2026-04-28
NCT07029217 A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas Memorial Sloan Kettering Cancer Center Recruiting 2026-02-17
NCT04834024 MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab… Beijing Mabworks Biotech Co., Ltd. Recruiting 2024-11-20
NCT05100862 A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants… BeOne Medicines Active, Not Recruiting 2026-09-11
NCT04680052 A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and… Incyte Corporation Active, Not Recruiting 2026-09-04
NCT02390869 Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for… Fondazione Italiana Linfomi - ETS Active, Not Recruiting 2026-08-19
NCT04224493 A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of… Epizyme, Inc. Active, Not Recruiting 2026-08-10
NCT07736950 A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without… Australasian Leukaemia and Lymphoma Group Not Yet Recruiting 2026-08-06
NCT06191744 Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral… Genmab Active, Not Recruiting 2026-08-04
NCT07719855 A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of… Ruijin Hospital Not Yet Recruiting 2026-07-22
NCT04712097 A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With… Hoffmann-La Roche Active, Not Recruiting 2026-07-10
NCT05409066 Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral… Genmab Active, Not Recruiting 2026-07-08
NCT05058404 Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment… Fondazione Italiana Linfomi - ETS Active, Not Recruiting 2026-06-26
NCT05888493 A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult… Novartis Pharmaceuticals Active, Not Recruiting 2026-04-17
NCT06097364 A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated… Regeneron Pharmaceuticals Active, Not Recruiting 2026-02-06
NCT07355283 IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in… ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Not Yet Recruiting 2026-01-27
See all 272 active Follicular Lymphoma trials with filters →

Top sponsors by active trials in this area

City of Hope Medical Center (13) · National Cancer Institute (NCI) (11) · M.D. Anderson Cancer Center (9) · Fondazione Italiana Linfomi - ETS (7) · University of Washington (7) · Genmab (5) · Mayo Clinic (5) · Sun Yat-sen University (5) · Institute of Hematology & Blood Diseases Hospital, China (4) · Memorial Sloan Kettering Cancer Center (4)

Get alerts when Follicular Lymphoma trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free